ガレクチン阻害剤治療薬のグローバル市場展望 2023年-2029年:天然、合成

■ 英語タイトル:Galectin Inhibitor Therapeutics Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート(データ管理コード:MMG23JU5575)■ 発行会社/調査会社:Market Monitor Global
■ 商品コード:MMG23JU5575
■ 発行日:2023年6月
■ 調査対象地域:グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野:医薬品&医療
■ ページ数:79
■ レポート言語:英語
■ レポート形式:PDF
■ 納品方式:Eメール(受注後2-3営業日)
■ 販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,250 ⇒換算¥494,000見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD4,225 ⇒換算¥642,200見積依頼/購入/質問フォーム
Enterprise User(閲覧人数制限なし)USD4,875 ⇒換算¥741,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能)
Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[ガレクチン阻害剤治療薬のグローバル市場展望 2023年-2029年:天然、合成]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

当調査レポートは次の情報を含め、世界のガレクチン阻害剤治療薬市場規模と予測を収録しています。・世界のガレクチン阻害剤治療薬市場:売上、2018年-2023年、2024年-2029年
・世界のガレクチン阻害剤治療薬市場:販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のガレクチン阻害剤治療薬市場は2022年に000Mドルと評価され、予測期間中に000%のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「天然」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

ガレクチン阻害剤治療薬のグローバル主要企業は、GlycoMimetics (US)、 Galectin Therapeutics Inc (US)、 G3 Pharmaceuticals (India)、 iTeos (US)、 MandalMed, Inc (US)、 Angion (US)、 Novartis AG (Switzerland)、 Galecto Biotech (Denmark)、 Pfizer Inc. (US)、 Lilly (US)などです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL(MMG)は、ガレクチン阻害剤治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界のガレクチン阻害剤治療薬市場:タイプ別、2018年-2023年、2024年-2029年
世界のガレクチン阻害剤治療薬市場:タイプ別市場シェア、2022年
・天然、合成

世界のガレクチン阻害剤治療薬市場:用途別、2018年-2023年、2024年-2029年
世界のガレクチン阻害剤治療薬市場:用途別市場シェア、2022年
・糖尿病、心不全、喘息、関節リウマチ、その他

世界のガレクチン阻害剤治療薬市場:地域・国別、2018年-2023年、2024年-2029年
世界のガレクチン阻害剤治療薬市場:地域別市場シェア、2022年
・北米:アメリカ、カナダ、メキシコ
・ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
・アジア:中国、日本、韓国、東南アジア、インド
・南米:ブラジル、アルゼンチン
・中東・アフリカ:トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業におけるガレクチン阻害剤治療薬のグローバル売上、2018年-2023年
・主要企業におけるガレクチン阻害剤治療薬のグローバル売上シェア、2022年
・主要企業におけるガレクチン阻害剤治療薬のグローバル販売量、2018年-2023年
・主要企業におけるガレクチン阻害剤治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
GlycoMimetics (US)、 Galectin Therapeutics Inc (US)、 G3 Pharmaceuticals (India)、 iTeos (US)、 MandalMed, Inc (US)、 Angion (US)、 Novartis AG (Switzerland)、 Galecto Biotech (Denmark)、 Pfizer Inc. (US)、 Lilly (US)

*************************************************************

・調査・分析レポートの概要
ガレクチン阻害剤治療薬市場の定義
市場セグメント
世界のガレクチン阻害剤治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のガレクチン阻害剤治療薬市場規模
世界のガレクチン阻害剤治療薬市場規模:2022年 VS 2029年
世界のガレクチン阻害剤治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのガレクチン阻害剤治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のガレクチン阻害剤治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分:天然、合成
ガレクチン阻害剤治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分:糖尿病、心不全、喘息、関節リウマチ、その他
ガレクチン阻害剤治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別ガレクチン阻害剤治療薬市場規模 2022年と2029年
地域別ガレクチン阻害剤治療薬売上・予測
北米市場:アメリカ、カナダ、メキシコ
ヨーロッパ市場:ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場:中国、日本、韓国、東南アジア、インド
南米市場:ブラジル、アルゼンチン
中東・アフリカ市場:トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル(企業概要、事業概要、主要製品、売上、ニュースなど)
GlycoMimetics (US)、 Galectin Therapeutics Inc (US)、 G3 Pharmaceuticals (India)、 iTeos (US)、 MandalMed, Inc (US)、 Angion (US)、 Novartis AG (Switzerland)、 Galecto Biotech (Denmark)、 Pfizer Inc. (US)、 Lilly (US)
...

This report aims to provide a comprehensive presentation of the global market for Galectin Inhibitor Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Galectin Inhibitor Therapeutics. This report contains market size and forecasts of Galectin Inhibitor Therapeutics in global, including the following market information:
Global Galectin Inhibitor Therapeutics Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Galectin Inhibitor Therapeutics Market Sales, 2018-2023, 2024-2029, (Kiloton)
Global top five Galectin Inhibitor Therapeutics companies in 2022 (%)
The global Galectin Inhibitor Therapeutics market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Natural Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Galectin Inhibitor Therapeutics include GlycoMimetics (US), Galectin Therapeutics Inc (US), G3 Pharmaceuticals (India), iTeos (US), MandalMed, Inc (US), Angion (US), Novartis AG (Switzerland), Galecto Biotech (Denmark) and Pfizer Inc. (US), etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Galectin Inhibitor Therapeutics manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Galectin Inhibitor Therapeutics Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (Kiloton)
Global Galectin Inhibitor Therapeutics Market Segment Percentages, by Type, 2022 (%)
Natural
Synthetic
Global Galectin Inhibitor Therapeutics Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (Kiloton)
Global Galectin Inhibitor Therapeutics Market Segment Percentages, by Application, 2022 (%)
Diabetes
Heart Failure
Asthma
Rheumatoid Arthritis
Other
Global Galectin Inhibitor Therapeutics Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (Kiloton)
Global Galectin Inhibitor Therapeutics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Galectin Inhibitor Therapeutics revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Galectin Inhibitor Therapeutics revenues share in global market, 2022 (%)
Key companies Galectin Inhibitor Therapeutics sales in global market, 2018-2023 (Estimated), (Kiloton)
Key companies Galectin Inhibitor Therapeutics sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
GlycoMimetics (US)
Galectin Therapeutics Inc (US)
G3 Pharmaceuticals (India)
iTeos (US)
MandalMed, Inc (US)
Angion (US)
Novartis AG (Switzerland)
Galecto Biotech (Denmark)
Pfizer Inc. (US)
Lilly (US)
Outline of Major Chapters:
Chapter 1: Introduces the definition of Galectin Inhibitor Therapeutics, market overview.
Chapter 2: Global Galectin Inhibitor Therapeutics market size in revenue and volume.
Chapter 3: Detailed analysis of Galectin Inhibitor Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Galectin Inhibitor Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Galectin Inhibitor Therapeutics capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

世界の市場調査レポート販売サイト(H&Iグローバルリサーチ株式会社運営)
*** レポート目次(コンテンツ)***

1 Introduction to Research & Analysis Reports
1.1 Galectin Inhibitor Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Galectin Inhibitor Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Galectin Inhibitor Therapeutics Overall Market Size
2.1 Global Galectin Inhibitor Therapeutics Market Size: 2022 VS 2029
2.2 Global Galectin Inhibitor Therapeutics Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Galectin Inhibitor Therapeutics Sales: 2018-2029
3 Company Landscape
3.1 Top Galectin Inhibitor Therapeutics Players in Global Market
3.2 Top Global Galectin Inhibitor Therapeutics Companies Ranked by Revenue
3.3 Global Galectin Inhibitor Therapeutics Revenue by Companies
3.4 Global Galectin Inhibitor Therapeutics Sales by Companies
3.5 Global Galectin Inhibitor Therapeutics Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Galectin Inhibitor Therapeutics Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Galectin Inhibitor Therapeutics Product Type
3.8 Tier 1, Tier 2 and Tier 3 Galectin Inhibitor Therapeutics Players in Global Market
3.8.1 List of Global Tier 1 Galectin Inhibitor Therapeutics Companies
3.8.2 List of Global Tier 2 and Tier 3 Galectin Inhibitor Therapeutics Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Galectin Inhibitor Therapeutics Market Size Markets, 2022 & 2029
4.1.2 Natural
4.1.3 Synthetic
4.2 By Type – Global Galectin Inhibitor Therapeutics Revenue & Forecasts
4.2.1 By Type – Global Galectin Inhibitor Therapeutics Revenue, 2018-2023
4.2.2 By Type – Global Galectin Inhibitor Therapeutics Revenue, 2024-2029
4.2.3 By Type – Global Galectin Inhibitor Therapeutics Revenue Market Share, 2018-2029
4.3 By Type – Global Galectin Inhibitor Therapeutics Sales & Forecasts
4.3.1 By Type – Global Galectin Inhibitor Therapeutics Sales, 2018-2023
4.3.2 By Type – Global Galectin Inhibitor Therapeutics Sales, 2024-2029
4.3.3 By Type – Global Galectin Inhibitor Therapeutics Sales Market Share, 2018-2029
4.4 By Type – Global Galectin Inhibitor Therapeutics Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Galectin Inhibitor Therapeutics Market Size, 2022 & 2029
5.1.2 Diabetes
5.1.3 Heart Failure
5.1.4 Asthma
5.1.5 Rheumatoid Arthritis
5.1.6 Other
5.2 By Application – Global Galectin Inhibitor Therapeutics Revenue & Forecasts
5.2.1 By Application – Global Galectin Inhibitor Therapeutics Revenue, 2018-2023
5.2.2 By Application – Global Galectin Inhibitor Therapeutics Revenue, 2024-2029
5.2.3 By Application – Global Galectin Inhibitor Therapeutics Revenue Market Share, 2018-2029
5.3 By Application – Global Galectin Inhibitor Therapeutics Sales & Forecasts
5.3.1 By Application – Global Galectin Inhibitor Therapeutics Sales, 2018-2023
5.3.2 By Application – Global Galectin Inhibitor Therapeutics Sales, 2024-2029
5.3.3 By Application – Global Galectin Inhibitor Therapeutics Sales Market Share, 2018-2029
5.4 By Application – Global Galectin Inhibitor Therapeutics Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Galectin Inhibitor Therapeutics Market Size, 2022 & 2029
6.2 By Region – Global Galectin Inhibitor Therapeutics Revenue & Forecasts
6.2.1 By Region – Global Galectin Inhibitor Therapeutics Revenue, 2018-2023
6.2.2 By Region – Global Galectin Inhibitor Therapeutics Revenue, 2024-2029
6.2.3 By Region – Global Galectin Inhibitor Therapeutics Revenue Market Share, 2018-2029
6.3 By Region – Global Galectin Inhibitor Therapeutics Sales & Forecasts
6.3.1 By Region – Global Galectin Inhibitor Therapeutics Sales, 2018-2023
6.3.2 By Region – Global Galectin Inhibitor Therapeutics Sales, 2024-2029
6.3.3 By Region – Global Galectin Inhibitor Therapeutics Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Galectin Inhibitor Therapeutics Revenue, 2018-2029
6.4.2 By Country – North America Galectin Inhibitor Therapeutics Sales, 2018-2029
6.4.3 US Galectin Inhibitor Therapeutics Market Size, 2018-2029
6.4.4 Canada Galectin Inhibitor Therapeutics Market Size, 2018-2029
6.4.5 Mexico Galectin Inhibitor Therapeutics Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Galectin Inhibitor Therapeutics Revenue, 2018-2029
6.5.2 By Country – Europe Galectin Inhibitor Therapeutics Sales, 2018-2029
6.5.3 Germany Galectin Inhibitor Therapeutics Market Size, 2018-2029
6.5.4 France Galectin Inhibitor Therapeutics Market Size, 2018-2029
6.5.5 U.K. Galectin Inhibitor Therapeutics Market Size, 2018-2029
6.5.6 Italy Galectin Inhibitor Therapeutics Market Size, 2018-2029
6.5.7 Russia Galectin Inhibitor Therapeutics Market Size, 2018-2029
6.5.8 Nordic Countries Galectin Inhibitor Therapeutics Market Size, 2018-2029
6.5.9 Benelux Galectin Inhibitor Therapeutics Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Galectin Inhibitor Therapeutics Revenue, 2018-2029
6.6.2 By Region – Asia Galectin Inhibitor Therapeutics Sales, 2018-2029
6.6.3 China Galectin Inhibitor Therapeutics Market Size, 2018-2029
6.6.4 Japan Galectin Inhibitor Therapeutics Market Size, 2018-2029
6.6.5 South Korea Galectin Inhibitor Therapeutics Market Size, 2018-2029
6.6.6 Southeast Asia Galectin Inhibitor Therapeutics Market Size, 2018-2029
6.6.7 India Galectin Inhibitor Therapeutics Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Galectin Inhibitor Therapeutics Revenue, 2018-2029
6.7.2 By Country – South America Galectin Inhibitor Therapeutics Sales, 2018-2029
6.7.3 Brazil Galectin Inhibitor Therapeutics Market Size, 2018-2029
6.7.4 Argentina Galectin Inhibitor Therapeutics Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Galectin Inhibitor Therapeutics Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Galectin Inhibitor Therapeutics Sales, 2018-2029
6.8.3 Turkey Galectin Inhibitor Therapeutics Market Size, 2018-2029
6.8.4 Israel Galectin Inhibitor Therapeutics Market Size, 2018-2029
6.8.5 Saudi Arabia Galectin Inhibitor Therapeutics Market Size, 2018-2029
6.8.6 UAE Galectin Inhibitor Therapeutics Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 GlycoMimetics (US)
7.1.1 GlycoMimetics (US) Company Summary
7.1.2 GlycoMimetics (US) Business Overview
7.1.3 GlycoMimetics (US) Galectin Inhibitor Therapeutics Major Product Offerings
7.1.4 GlycoMimetics (US) Galectin Inhibitor Therapeutics Sales and Revenue in Global (2018-2023)
7.1.5 GlycoMimetics (US) Key News & Latest Developments
7.2 Galectin Therapeutics Inc (US)
7.2.1 Galectin Therapeutics Inc (US) Company Summary
7.2.2 Galectin Therapeutics Inc (US) Business Overview
7.2.3 Galectin Therapeutics Inc (US) Galectin Inhibitor Therapeutics Major Product Offerings
7.2.4 Galectin Therapeutics Inc (US) Galectin Inhibitor Therapeutics Sales and Revenue in Global (2018-2023)
7.2.5 Galectin Therapeutics Inc (US) Key News & Latest Developments
7.3 G3 Pharmaceuticals (India)
7.3.1 G3 Pharmaceuticals (India) Company Summary
7.3.2 G3 Pharmaceuticals (India) Business Overview
7.3.3 G3 Pharmaceuticals (India) Galectin Inhibitor Therapeutics Major Product Offerings
7.3.4 G3 Pharmaceuticals (India) Galectin Inhibitor Therapeutics Sales and Revenue in Global (2018-2023)
7.3.5 G3 Pharmaceuticals (India) Key News & Latest Developments
7.4 iTeos (US)
7.4.1 iTeos (US) Company Summary
7.4.2 iTeos (US) Business Overview
7.4.3 iTeos (US) Galectin Inhibitor Therapeutics Major Product Offerings
7.4.4 iTeos (US) Galectin Inhibitor Therapeutics Sales and Revenue in Global (2018-2023)
7.4.5 iTeos (US) Key News & Latest Developments
7.5 MandalMed, Inc (US)
7.5.1 MandalMed, Inc (US) Company Summary
7.5.2 MandalMed, Inc (US) Business Overview
7.5.3 MandalMed, Inc (US) Galectin Inhibitor Therapeutics Major Product Offerings
7.5.4 MandalMed, Inc (US) Galectin Inhibitor Therapeutics Sales and Revenue in Global (2018-2023)
7.5.5 MandalMed, Inc (US) Key News & Latest Developments
7.6 Angion (US)
7.6.1 Angion (US) Company Summary
7.6.2 Angion (US) Business Overview
7.6.3 Angion (US) Galectin Inhibitor Therapeutics Major Product Offerings
7.6.4 Angion (US) Galectin Inhibitor Therapeutics Sales and Revenue in Global (2018-2023)
7.6.5 Angion (US) Key News & Latest Developments
7.7 Novartis AG (Switzerland)
7.7.1 Novartis AG (Switzerland) Company Summary
7.7.2 Novartis AG (Switzerland) Business Overview
7.7.3 Novartis AG (Switzerland) Galectin Inhibitor Therapeutics Major Product Offerings
7.7.4 Novartis AG (Switzerland) Galectin Inhibitor Therapeutics Sales and Revenue in Global (2018-2023)
7.7.5 Novartis AG (Switzerland) Key News & Latest Developments
7.8 Galecto Biotech (Denmark)
7.8.1 Galecto Biotech (Denmark) Company Summary
7.8.2 Galecto Biotech (Denmark) Business Overview
7.8.3 Galecto Biotech (Denmark) Galectin Inhibitor Therapeutics Major Product Offerings
7.8.4 Galecto Biotech (Denmark) Galectin Inhibitor Therapeutics Sales and Revenue in Global (2018-2023)
7.8.5 Galecto Biotech (Denmark) Key News & Latest Developments
7.9 Pfizer Inc. (US)
7.9.1 Pfizer Inc. (US) Company Summary
7.9.2 Pfizer Inc. (US) Business Overview
7.9.3 Pfizer Inc. (US) Galectin Inhibitor Therapeutics Major Product Offerings
7.9.4 Pfizer Inc. (US) Galectin Inhibitor Therapeutics Sales and Revenue in Global (2018-2023)
7.9.5 Pfizer Inc. (US) Key News & Latest Developments
7.10 Lilly (US)
7.10.1 Lilly (US) Company Summary
7.10.2 Lilly (US) Business Overview
7.10.3 Lilly (US) Galectin Inhibitor Therapeutics Major Product Offerings
7.10.4 Lilly (US) Galectin Inhibitor Therapeutics Sales and Revenue in Global (2018-2023)
7.10.5 Lilly (US) Key News & Latest Developments
8 Global Galectin Inhibitor Therapeutics Production Capacity, Analysis
8.1 Global Galectin Inhibitor Therapeutics Production Capacity, 2018-2029
8.2 Galectin Inhibitor Therapeutics Production Capacity of Key Manufacturers in Global Market
8.3 Global Galectin Inhibitor Therapeutics Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Galectin Inhibitor Therapeutics Supply Chain Analysis
10.1 Galectin Inhibitor Therapeutics Industry Value Chain
10.2 Galectin Inhibitor Therapeutics Upstream Market
10.3 Galectin Inhibitor Therapeutics Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Galectin Inhibitor Therapeutics Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/



※注目の調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(MMG23JU5575 )"ガレクチン阻害剤治療薬のグローバル市場展望 2023年-2029年:天然、合成" (英文:Galectin Inhibitor Therapeutics Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。